Medical - Devices
Compare Stocks
2 / 10Stock Comparison
VERO vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
VERO vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $499K | $160.44B |
| Revenue (TTM) | $59M | $10.58B |
| Net Income (TTM) | $-55M | $2.98B |
| Gross Margin | 64.4% | 66.3% |
| Operating Margin | -59.0% | 30.5% |
| Forward P/E | — | 43.7x |
| Total Debt | $43M | $303M |
| Cash & Equiv. | $4M | $3.37B |
VERO vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Apr 26 | Return |
|---|---|---|---|
| Venus Concept Inc. (VERO) | 100 | 0.1 | -99.9% |
| Intuitive Surgical,… (ISRG) | 100 | 238.4 | +138.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VERO vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
In this particular matchup, VERO is outpaced on most metrics by others in the set.
ISRG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.02
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.6% 10Y total return vs VERO's -100.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs VERO's -15.1% | |
| Quality / Margins | 28.2% margin vs VERO's -92.8% | |
| Stability / Safety | Beta 1.02 vs VERO's 1.43, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -14.8% vs VERO's -88.6% | |
| Efficiency (ROA) | 14.8% ROA vs VERO's -88.6%, ROIC 15.0% vs -39.8% |
VERO vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
VERO vs ISRG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 179.7x VERO's $59M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to VERO's -92.8%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $59M | $10.6B |
| EBITDAEarnings before interest/tax | -$31M | $3.8B |
| Net IncomeAfter-tax profit | -$55M | $3.0B |
| Free Cash FlowCash after capex | -$21M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +64.4% | +66.3% |
| Operating MarginEBIT ÷ Revenue | -59.0% | +30.5% |
| Net MarginNet income ÷ Revenue | -92.8% | +28.2% |
| FCF MarginFCF ÷ Revenue | -35.2% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -8.2% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -8.5% | +18.8% |
Valuation Metrics
VERO leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $498,989 | $160.4B |
| Enterprise ValueMkt cap + debt − cash | $39M | $157.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | 57.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 43.67x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.64x |
| EV / EBITDAEnterprise value multiple | — | 43.44x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 15.94x |
| Price / BookPrice ÷ Book value/share | 0.07x | 9.13x |
| Price / FCFMarket cap ÷ FCF | — | 64.42x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-17 for VERO. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to VERO's 15.16x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs VERO's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -17.4% | +16.9% |
| ROA (TTM)Return on assets | -88.6% | +14.8% |
| ROICReturn on invested capital | -39.8% | +15.0% |
| ROCEReturn on capital employed | -54.2% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 15.16x | 0.02x |
| Net DebtTotal debt minus cash | $39M | -$3.1B |
| Cash & Equiv.Liquid assets | $4M | $3.4B |
| Total DebtShort + long-term debt | $43M | $303M |
| Interest CoverageEBIT ÷ Interest expense | -9.69x | — |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $16,086 today (with dividends reinvested), compared to $9 for VERO. Over the past 12 months, ISRG leads with a -14.8% total return vs VERO's -88.6%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.2% vs VERO's -79.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -82.3% | -19.6% |
| 1-Year ReturnPast 12 months | -88.6% | -14.8% |
| 3-Year ReturnCumulative with dividends | -99.1% | +49.0% |
| 5-Year ReturnCumulative with dividends | -99.9% | +60.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | +556.9% |
| CAGR (3Y)Annualised 3-year return | -79.4% | +14.2% |
Risk & Volatility
ISRG leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ISRG is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than VERO's 1.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ISRG currently trades 74.8% from its 52-week high vs VERO's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.43x | 1.02x |
| 52-Week HighHighest price in past year | $12.93 | $603.88 |
| 52-Week LowLowest price in past year | $0.26 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +2.1% | +74.8% |
| RSI (14)Momentum oscillator 0–100 | 42.9 | 42.2 |
| Avg Volume (50D)Average daily shares traded | 9K | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $622.60 |
| # AnalystsCovering analysts | — | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% |
ISRG leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VERO leads in 1 (Valuation Metrics).
VERO vs ISRG: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VERO or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -15. 1% for Venus Concept Inc. (VERO). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 4x trailing P/E (43. 7x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VERO or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +60. 9%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: ISRG returned +556. 9% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VERO or ISRG?
By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.
(ISRG) is the lower-risk stock at 1. 02β versus Venus Concept Inc. 's 1. 43β — meaning VERO is approximately 40% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — VERO or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -15. 1% for Venus Concept Inc. (VERO). On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc. grew EPS 22. 6% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VERO or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -41. 9% for VERO. At the gross margin level — before operating expenses — VERO leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VERO or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VERO or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Intuitive Surgical, Inc.
(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +556. 9% 10Y return). Both have compounded well over 10 years (ISRG: +556. 9%, VERO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VERO and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VERO is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.